Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21539126 | 0.89 | ATM (0.46) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL22409489 | 0.87 | ATM (0.48) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL19014888 | 0.87 | ATM (0.48) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL30404588 | 0.87 | ATM (0.41) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL21179138 | 0.87 | ATM (0.44) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL2950848 | 0.85 | ATM (0.46) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL31450971 | 0.85 | ATM (0.38) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL30405443 | 0.85 | ATM (0.39) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL22428875 | 0.84 | CTSK (0.39) | ATMCTSKPPARGPPARAPPARD | |
| SCHEMBL30405268 | 0.83 | ATM (0.41) | ATMCTSKPPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107606-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | ATM 2205/4885CTSK 477/4885PPARG 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.